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Introduction. Tobacco use increases risks for numerous diseases, including respiratory illnesses. We examined the literature to
determine whether a history of tobacco use increases risks for adverse outcomes among COVID-19 patients. Methods. We
conducted a systematic search of PubMed, LitCovid, Scopus, and Europe PMC (for preprints) using COVID-19 and tobaccorelated terms. We included studies of human subjects with lab-conﬁrmed COVID-19 infections that examined tobacco use
history as an exposure and used multivariable analyses. The data was collected between March 31st, 2020, and February 20th,
2021. Outcomes included mortality, hospitalization, ICU admission, mechanical ventilation, and illness severity. Results.
Among the 39 studies (33 peer-reviewed, 6 preprints) included, the most common outcome assessed was mortality (n = 32).
The majority of these studies (17/32) found that tobacco use increased risk, one found decreased risk, and 14 found no
association. Tobacco use was associated with increased risk of hospitalization in 7 of 10 studies, ICU admission in 6 of 9
studies, mechanical ventilation in 2 of 6 studies, and illness severity in 3 of 9 studies. One study found that tobacco use history
increased risk of pulmonary embolism in COVID-19 patients. Tobacco use was found to compound risks associated with
diabetes (n = 1), cancer (n = 2), and chronic liver disease (n = 1). Conclusion. There is strong evidence that tobacco use
increases risks of mortality and disease severity/progression among COVID-19 patients. Public health eﬀorts during the
pandemic should encourage tobacco users to quit use and seek care early and promote vaccination and other preventive
behaviors among those with a history of tobacco use.

1. Introduction
The emergence of COVID-19 in the last two years represents
a grave threat to global health. Researchers have worked rapidly to better understand the risk factors associated with
COVID-19, in order to prevent infections and reduce the
severity of illness in those infected. Initially considered a
respiratory infection, COVID-19 is now understood to be a
systemic infection, which can cause a wide variety of complications throughout the body. SARS-CoV-2 commonly targets Angiotensin-Converting Enzyme 2 (ACE2) receptors
in a host’s lungs and downregulates ACE2 expression [1].
ACE2 receptors are part of the Renin-Angiotensin System
(RAS), which plays a complex role in regulating cardiovas-

cular, renal, and metabolic functions. Thus, individuals living with comorbidities associated with RAS dysregulation
(e.g., kidney disease, diabetes mellitus, and cardiovascular
and pulmonary diseases) are at increased risk of severe
COVID-19 [2, 3].
Tobacco use is a well-documented risk factor for hypertension, lung disease, cardiovascular disease, cancer, and
diabetes and is a leading cause of chronic disease and death
worldwide [4]. Additionally, cigarette smoking is a known
risk factor for contracting infectious respiratory diseases
such as inﬂuenza, tuberculosis, and MERS, as well as exacerbating the outcomes of those infections [5, 6]. Research has
found that smoking increases ACE2 receptors in the lungs,
indicating that smokers may be more vulnerable to infection
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[7, 8]. While the exact mechanisms of the interaction
between tobacco and the RAS are complex, evidence shows
that nicotine itself dysregulates the RAS [2]. Since preexisting dysregulation of the RAS and its associated comorbidities worsen the severity and outcomes of COVID-19,
understanding the impact of tobacco use on COVID-19 outcomes could signiﬁcantly impact both prevention and treatment of COVID-19.
Given the explosion of research on SARS-CoV-2, systematic reviews of the literature are needed to inform
evidence-based policies and practices to reduce the population impact of COVID-19. Since tobacco is a known risk factor for other infectious diseases, several reviews have focused
on its impact on COVID-19 (see Table 1). The earliest
review of COVID-19 and smoking that the authors are
aware of was completed in March 2020 and provided initial
ﬁndings from January to February 2020 [9]. Reviewing ﬁve
relatively small studies, all from China, the study concluded
that tobacco smoking likely had a negative impact on
COVID-19 disease progression and outcomes. Several
reviews followed in early 2020, all of which relied heavily
on relatively small studies from China [10–12]. In June
2020, Gulsen et al. conducted a systematic review and
meta-analysis which included 16 studies, 14 of which were
from China and 2 of which were from the United States.
This study more ﬁrmly concluded that a history of smoking
is associated with severe COVID-19 [13].
As more research was published in the summer and fall
of 2020, reviews were able to include studies from a wider
range of countries. One meta-analysis of 10 studies published in October 2020 included studies from Italy, Thailand,
and the United Kingdom and speciﬁcally analyzed the association between smoking and mortality in COVID-19
patients [14]. However, this study drew only from one database (PubMed) and did not examine outcomes beyond mortality. Another review and meta-analysis included 47 peerreviewed articles published between January and late May
2020 and analyzed the impact of smoking behavior on
COVID-19 progression and mortality [15]. This may be
the largest review to date speciﬁcally focused on tobacco
use and COVID-19 outcomes, and it concluded that smoking is an independent risk factor for COVID-19 severity
and death. However, some of the included studies had very
small numbers of smokers (studies were excluded when the
number of smokers was “zero or omitted”) and the study
did not have a requirement regarding how COVID-19 was
diagnosed. A literature review exploring the relationship
between tobacco-related comorbidities and COVID-19 outcomes was published in November 2020 [16]. This review
included 23 studies published between January and September 2020. Although this was not a systematic review, it did
ﬁnd an association between tobacco use, cardiopulmonary
diseases, and negative COVID-19 outcomes.
Finally, the most recent review at the time of this writing
included 40 studies published up to December 12, 2020 [17].
This systematic review and meta-analysis found that current
and former smoking increased the risk of COVID-19 severity and death. Of the studies included, 19 were from in
China, 12 were from the US, and the rest were from other
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countries. Although this review assessed the quality of
included studies, it did not have requirements regarding
how COVID-19 was diagnosed or the number of smokers
a study had to include in its sample.
The current study was aimed at identifying the impact of
tobacco use on COVID-19 outcomes. Speciﬁcally, this
review was aimed at adding to the existing literature in three
main ways: (1) studies included had a sample of 30 or more
current and former smokers, (2) only laboratory-conﬁrmed
cases of COVID-19 were included, and (3) to the extent possible, this review explored speciﬁc outcomes beyond general
disease severity and mortality. Additionally, since early studies have already been heavily reviewed, we only included
studies that completed data collection after March 31,
2020. Findings from this study can improve our understanding of the role of tobacco use as a risk factor for SARS-CoV2 and facilitate our ability to draw actionable conclusions
based on the available data.

2. Methods and Materials
This systematic literature review identiﬁed articles through
keyword searches using the following databases: PubMed,
Scopus, LitCovid, and Europe PMC (for preprints). The full
list of search terms can be found in the Appendix and
includes three themes: (i) terms related to tobacco such as
“tobacco,” “smoking,” and “vaping”; (ii) terms related to
COVID-19, including “SARS-CoV-2” and “novel coronavirus”; and (iii) terms related to outcomes, such as “mortality”
and “hospitalization.”
Inclusion criteria for studies were as follows: (i) written
in English; (ii) collected data between March 31, 2020, and
February 20, 2021; (iii) sample size of 30 or more current
or former tobacco users; (iv) lab-conﬁrmed COVID-19 diagnosis; (v) assessed history of tobacco use as an exposure; and
(vi) used multivariable analysis. Studies that were published
in other languages; completed data collection before March
31, 2020; focused on animal subjects; relied on selfreported or symptom-diagnosed COVID-19; had fewer than
30 current or former tobacco users; conducted only univariate or descriptive analyses; or were unrelated to tobacco
use were excluded. Case studies, ecological studies, in vitro
and in silico studies, and Mendelian randomization studies
were also excluded. Other reviews were included in the ﬁrst
stage of the search to screen for references and were then
excluded.
One researcher (JB) conducted an initial screening of
titles and abstracts to eliminate articles that did not meet
the inclusion criteria. Two researchers (JB and NK) reviewed
the remaining titles and abstracts more closely to further
eliminate articles that did not meet inclusion criteria. JB
and NK then conducted a full-text review of included articles. One researcher (JB) conducted the data extraction for
ﬁnal analysis.
Researchers used a wide variety of metrics. Lab-conﬁrmed
COVID-19 was primarily based on a positive result on an RTPCR test. However, a few studies conﬁrmed COVID-19 using
other lab tests such as antibody or serum tests or CT radiology
scans. Diagnoses based on symptoms were excluded. The type
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Table 1: Early and later reviews on tobacco use and COVID-19.

Author

Date

Studies

Conclusions

Notable limitations

March
2020

Smoking likely had a negative impact on
Vardavas et al.
5 from China
Very small sample, very early data
COVID-19 disease progression and outcomes
More evidence is needed if tobacco use may
April
Berlin et al.
6 from China
be a risk factor for both transmission and
Small sample, early data
2020
negative outcomes
Smokers are underrepresented among
Relies on early data exclusively from China;
May
hospitalized patients; former smokers have
unadjusted for confounding factors
13 from China
Farsalinos et al.
2020
higher odds of adverse outcomes than current
including sociodemographic factors
smokers; nicotine may be protective
Relies heavily on early data from China;
June
14 from China, History of smoking is associated with severe
Gulsen et al.
classiﬁcations of both smokers and
2020
2 from Italy
COVID-19
COVID-19 patients varied
Does not include research published after
May 25, 2020; includes studies with very
Sept
Patanavanich
47 from 16
Smoking is an independent risk factor for
small (>0) smoking populations; no
2020,
et al.
countries
COVID-19 severity and death
requirement regarding COVID-19
preprint
diagnosis
10 from various
Smoking doubles the risk of mortality in
Used only PubMed; included mortality as
Oct
countries
Salah et al.
COVID-19 patients
an outcome
2020
(China, UK,
Thailand)
23 from various
Tobacco use is associated with comorbidities
Nov
countries
which increase the likelihood of negative
Literature review; not systematic
Gupta et al.
2020
(China, US,
COVID-19 outcomes
Italy)
No requirement regarding COVID-19 as
Umnuaypornlert
Feb
40 from 8
Tobacco use increases the risk of disease
diagnosis; no minimum number of smokers
et al.
2021
countries
severity and death in COVID-19 patients
to be included in studies

of tobacco use discussed in almost all the studies (n = 38) was
combustible smoking. One study focused on smokeless
tobacco. Tobacco use was most commonly reported as ever
vs. never use (n = 15) or never/former/current use (n = 13).
Two studies analyzed diﬀerences in pack-years smoked, where
pack-years referred to the number of packs smoked per day
times the number of years smoked.
Finally, “outcome” was deﬁned as what happened after a
person was infected with COVID-19. Outcomes for this
analysis included the following: mortality (n = 32), hospitalization (n = 10), ICU admission (n = 9), mechanical ventilation (n = 6), and severity of illness (n = 9). Studies deﬁned
“severity” in diﬀerent ways. For example, Adrish et al. [18]
deﬁned severity on the basis of pneumonia and hypoxia status, while Mendy et al. [19] deﬁned severity as admission to
ICU or death during hospitalization. Studies focused on the
incidence or transmission of COVID-19 were excluded.

3. Results
The initial search, done on February 20, 2021, identiﬁed
5,980 articles. Of these articles, 472 were published before
December 2019 and removed from the Scopus search, leaving 5,508 citations. The searches were uploaded to Covidence for screening. Covidence identiﬁed 838 duplicates,
which were reviewed for conﬁrmation and then removed,

leaving 4,670 articles to screen. The breakdown of the results
can be seen in the PRISMA chart in Figure 1.
In the ﬁrst round of title and abstract screening, 4,223
articles were excluded. Many of these (n = 1,743) were thematically irrelevant. For example, they discussed adapting
medical procedures in the context of COVID-19 or were
otherwise unrelated to tobacco use (n = 1,056), focused on
behavior or socioeconomic impacts (n = 694), focused on
diseases other than COVID-19 (n = 420), or focused on incidence risk (n = 219) or were in silico, in vitro, or animal
studies (n = 148). Two of the authors (JB and NK) reviewed
the titles and abstracts of the remaining 447 articles. The second round of review eliminated another 309 articles, including ecological studies, case studies, reviews, and
commentaries. The remaining 138 articles were included in
the full-text review. Of these, a further 99 were excluded
for the following reasons: only included data collected before
March 31, 2020 (n = 20), sample sizes included fewer than
30 current or former tobacco users (n = 18), did not include
smoking in a multivariable analysis (n = 17), included cases
of COVID-19 not conﬁrmed by lab results (n = 11), did
not analyze the relationship between tobacco use and
COVID-19 outcomes (n = 6), and did not include smoking
as an independent variable in the analysis (n = 4). Additionally, 21 studies were excluded as they were duplicates, used
the wrong study designs, or contained the wrong outcomes
(e.g., incidence of COVID-19 rather than severity), and a
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5,508 records
found

838 duplicates
removed

4,670 records
screened

4,226
excluded

444 records
re-screened

309
excluded

138 records
full-text review

99
excluded

39 final
analysis

Reasons for exclusion:
– 20 pre-March 2020
– 18 small sample
– 17 no multivariable analysis
– 11 symptom diagnosis of COVID -19
– 6 wrong comparisons
– 4 smoking not an independent variable
– 2 retractions
– 21 duplicates, wrong study designs, or
wrong outcomes (e.g., incidence)

Figure 1: PRISMA chart.

further 2 studies were excluded because the articles were
retracted.
In total, 39 studies were included in this review. At the
time of the initial review, 29 of these studies were peerreviewed manuscripts and 10 were preprints. Four preprints
were subsequently published and are included in the peerreviewed count. The characteristics of the studies can be seen
in Table 2, with peer-reviewed and preprint studies listed
separately. Studies had sample sizes that ranged from 101
to 406,793, with history of tobacco use sample sizes ranging
from 35 to 24,484. Fourteen countries were represented by
the studies, with 45% of studies done in the United States.
Twenty-six studies used retrospective observational cohort
designs, 8 used prospective/longitudinal study designs, 3
used case-control designs, and 2 used cross-sectional
designs.
3.1. Mortality. Mortality was the most common outcome
used across studies to assess the impact of tobacco use on
COVID-19. Out of the 39 studies, 32 assessed the association
between tobacco use and mortality. Of the 28 peer-reviewed
articles that assessed mortality, 12 found no signiﬁcant association, 15 found an increased risk of death, and one found a
decreased risk of death. Of the 4 preprints that assessed mortality, 2 did not ﬁnd a signiﬁcant association and 2 found
that tobacco use increased the risk of death. Seven articles
did not report on mortality. The one article that found a signiﬁcantly decreased risk of death came from Mexico, using
Ministry of Health data [20]. However, in a univariate analysis, the authors found a signiﬁcant risk in men but not in
women, which they suggested could be due to a doseresponse relationship, as men are much heavier smokers
than women.
A few studies focused on speciﬁc populations. Two studies among cancer patients with COVID-19 both found that
tobacco use signiﬁcantly increased the risk of mortality,
and this was most common for patients with respiratory
tract cancers [21, 22]. A study on chronic liver disease
patients with COVID-19 also found a signiﬁcantly increased
risk in this population [23].

Regarding mortality data, not all studies divided their
data in the same way. Some studies analyzed former and current tobacco users separately. There was a trend in studies
ﬁnding more signiﬁcant risk in former smokers compared to
current smokers. One factor that could explain this trend is
that the pool of former smokers tended to be much larger than
current smokers—often 3-5 times larger. Likewise, in some
studies, the number of patients who died was very small. Even
with an initial pool of 100 smokers, some studies only
observed 2 or 3 deaths within that group, making statistical
analysis diﬃcult. Some of the studies that did not ﬁnd a significant association in multivariable analysis found increased
mortality risk in univariate analysis [18, 24].
One study identiﬁed a dose-response eﬀect based on
pack-years, with those with a history of 30 pack-years or
more having a signiﬁcantly higher risk of death than those
with a lower pack-year history [25]). As suggested by the
Parra-Bracamonte et al. study, there might be a doseresponse relationship between tobacco use history and
COVID-19 mortality risk.
3.2. Disease Severity and Progression. In addition to mortality, 23 studies (19 peer-reviewed and 4 preprints) assessed
a variety of other indicators for disease severity and progression (see Table 2). Eight (7 peer-reviewed and 1 preprint)
studies found no signiﬁcant association between tobacco
use and the COVID-19 outcomes they measured. However,
15 (12 peer-reviewed and 3 preprints) studies found a significantly higher risk of disease severity or progression for people with a history of tobacco use. None of these 23 studies
reported a signiﬁcantly decreased risk.
Studies deﬁned severity and progression in a wide variety
of ways. The most common measures were hospitalization
(n = 10), ICU admission (n = 9), the need for mechanical
ventilation (n = 6), and severity (n = 9). Across the studies,
tobacco smokers were found to be at signiﬁcantly higher risk
of hospitalization (n = 7) and ICU admission (n = 6) than
nonsmokers. Two studies found smokers at increased risk
of mechanical ventilation, and three found smokers to be
at increased risk of severe or critical illness.

June
2020

July
2020

Jan
2021

Feb
2021

July
2020

Dec
2020

Sept
2020

Oct
2020

BelloChavolla,
O.Y. et al.

Pérez-Sastré,
M.A. et al.

Lowe, K.E.
et al.

Lohia, P.
et al.

Hamer, M.
et al.

VilchesMoraga, A.
et al.

Kim, D. et al.

Adrish, M.
et al.

Di
Castelnuovo,
A. et al.
Raines, A.M.
et al.

USA

Dec
2020

Ho, K.S. et al.

Retrospective
multicenter cohort

Retrospective
multicenter cohort

Retrospective
cohort

Retrospective
cohort

1,871

7,102

16,752

20,804

9,991

10,131

Longitudinal
multicenter cohort

Retrospective
multicenter cohort

331,298

Participants

Retrospective
cohort

Study design

704 (37.6%)

1,082 (15.2%)

1,340 (8%)

∗

Italy

USA

Oct
2020

Feb
2021

USA

Retrospective
observational
multicenter cohort
Retrospective
cohort

Retrospective
cohort

440

3,894

1,173

250 (56.8%)

319 (8.2%)

336 (28.6%)

aOR = 2:28, p < 0:01

NS

NS

∗

∗

∗

∗

∗

∗

∗

∗

∗

∗

∗

47% smoke
vs. 37%
nonsmoke,
p = 0:003
47% smoke vs.
37% nonsmoke,
p = 0:005
∗

NS

∗

∗

∗

∗

∗

∗

∗

∗

∗

Severity

∗

∗

∗

NS

aOR = 1:25, p =
0:03

OR = 1:26, p = 0:02;
aOR NS

∗

∗

NS

aOR = 1:41
aOR = 1:55 (10aOR = 1:89, p < 0:05 (10-30 pkyr) &
30) and 1.69
(>30 pkyr), NS for less 2.25 (+30 pkyr),
(+30), p < 0:05
p < 0:05

NS

∗

NS

NS

∗

Mechanical
ventilation

Prev ratio = 0:90
, p < 0:05

NS

∗

∗

ICU admission

∗

OR = 1:2, p <
0:05

NS

NS

∗

Hospitalization

NS

NS

NS

2,212 (22.1%);
1,279 (26.1%)
hospitalized
1,815 (8.7%)

NS

OR = 0:931, p = 0:0151

Mortality

5,212 (51.4%)

24,484 (7.4%)

Smokers

406 (53.4%)
387,109 (760
aRR = 1:36, p <
(37k/9.7%
∗
UK
Prospective cohort with COVID0:05
current smokers
19)
in whole cohort)
Multicenter
∗
∗
UK & Italy
observational
831
361 (43.4%)
cohort
Retrospective
HR = 2:99, p = 0:001
∗
(current smokers), NS
USA
observational
867
354 (40.7%)
multicenter cohort
for former

USA

USA

Mexico

Mexico

USA

Sept
2020

Location

Mexico

Month
and
year

Dec
2020

ParraBracamonte,
G.M. et al.
Ioannou,
G.N. et al.

Author

Table 2: Study characteristics and results.
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Egypt

China

Jan
2021

Sept
2020

Oct
2020

Nov
2020

July
2020

Sept
2020

Oct
2020

Nov
2020

Aug
2020

June
2020

Sept
2020
Oct
2020

July
2020

Saurabh, S.
et al.

Soares,
R.C.M. et al.

Alharthy, A.
et al.

Abohamr,
S.I. et al.

Garassino,
M.C. et al.

Abbas, H.M.
et al.

Ullah, A.D.
et al.

Ragab, E.
et al.

Chen, L. et al.

Killerby,
M.E. et al.

Chetboun,
M. et al.
Chand, S.
et al.

Palaiodimos,
L. et al.

USA

USA

6 countries

USA

UK

Iraq

8 countries

Saudi
Arabia

Saudi
Arabia

Brazil

India

Bangladesh

Oct
2020

Islam, M.Z.
et al.

Location

Month
and
year

Author

284

212

Cross-sectional
observational
follow-up
Retrospective
single-center
cohort

Retrospective
cohort

Retrospective
multicenter cohort
Retrospective case
series

Retrospective
cohort

Retrospective
multicenter cohort

200

300

1,461

531

1,859

240

196

Cross-sectional &
longitudinal
multicenter
observational
cohort

Retrospective
cohort

768

352

Retrospective case
series

Retrospective
single center cohort

10,713

911

Prospective
unmatched casecontrol study

Retrospective
multicenter cohort

1,016

Participants

Retrospective
single center cohort

Study design

65 (32.5%)

67 (22.3%)

83 (6.5%) (data
for 1,275)

91 (17.1%)

111 (6%)

116 (48.3%)

126 (59.4%)

141 (49.6%)

159 (81.1%)

160 (20.8%)

174 (49.4%)

209 (1.95%)

NS

∗

∗

RR = 1:35, p = 0:01

∗

∗

∗

∗

aOR = 2:3, p <
0:05
∗

∗

∗

∗

∗

∗

∗

NS

∗

∗

∗

∗

∗

∗

∗

OR = 2:991, p =
0:001

∗

∗

∗

∗

∗

Mechanical
ventilation

∗

∗

∗

NS

∗

HR = 1:84, p = 0:009

∗

∗

∗

HR = 1:36, p = 0:014
(smoke only); HR =
1:66, p < 0:01 (smoke
+ diabetes)
NS

∗

∗

∗

∗

OR = 2:91, p <
0:001

OR = 3:18, p < 0:05

OR = 7:018, p = 0:001

OR = 3:0, p = 0:025

NS

∗

∗

ICU admission

∗

∗

OR = 3:516, p < 0:05,
RR = 3:33;
aOR for smokeless NS

185 (18.2%); 40
smokeless
tobacco (3.9%)
80 (8.8%); 139
(15.3%)
smokeless
tobacco
NS

Hospitalization

Mortality

Smokers

Table 2: Continued.

OR = 2:1, p
= 0:022

∗

∗

∗

∗

OR = 3:31,
p = 0:005

∗

NS

∗

∗

∗

∗

NS

NS

Severity
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USA

USA

Jan
2021
Jan
2021

June
2020

June
2020

May
2020

Nov
2020

June
2020

Jan
2021

Ferrari, B.L.
et al.
Wallis, T.
et al.
Preprints

Wang, A.
et al.

Israel, A.
et al.

Khawaja, A.
et al.

Romero, G.F.
et al.

Mendy, A.
et al.

Hasan, M.
et al.

689
600

Prospective
observational
cohort

577

Retrospective
multicenter cohort

Retrospective
cohort

24,906 (4,151
cases)

7,592

101

198

1,572 (20.7%)

35 (35%)

41 (21%)

44 (4%)

54 (17%)

1,697 (407
assessed for
predictors of
mortality)
1096

56 (36.4%)

61 (38.4%)

Smokers

154

159

Participants

106 (17.6%)

170 (24.7%)

268 (46.4%)

889 (21.4%)
(cases)
331 (54%) (40k/
406,793 (605
10% current
Prospective cohort with COVIDsmokers in whole
19)
cohort)
Case-control

Retrospective
multicenter cohort

Longitudinal
multicenter cohort
Prospective single
center cohort

Retrospective
cohort

Retrospective
multicenter cohort

Retrospective casecontrol
Retrospective
cohort (2 sites)

Study design

∗

∗

∗
aOR = 1:27, p = 0:041
(former); NS for
current

aOR = 2:34, p =
0:01

aOR = 2:01, p
< 0:001
∗

∗

NS

∗

aOR = 1:99, p = 0:03
(former); NS for
current

∗

∗

OR = 1:39, p <
0:001
∗

NS

∗

∗

∗

∗

∗

NS

∗

Former: 15.5%
(p = 0:09),
current: 19.8%
(p = 0:022)
∗

∗

NS

∗

∗

∗

∗

∗

∗

∗

Severity

∗

∗

∗

∗

∗

∗

OR = 5:86, p =
0:015
∗

∗

∗

∗

Mechanical
ventilation

∗

∗

∗

ICU admission

∗

NS

∗

∗

∗

∗

∗

Hospitalization

OR = 3:4, p = 0:01

OR = 10:09, p = 0:032

OR = 2:72, p = 0:031

OR = 5:47, p = 0:008

NS

Mortality

OR: odds ratio; aOR: adjusted odds ratio; HR: hazard ratio; RR: relative risk; NS: not signiﬁcant; pkyr: pack years. ∗ Not assessed.
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L,G. et al.

Badr, O. et al.

Author
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A few other outcomes were also assessed. One study
found that smokers were more likely to have chest X-ray
abnormalities 12 weeks after hospitalization, which correlated with longer hospital stays and longer recovery times
[26]. Another study also indicated that smokers may be at
risk of longer hospital stays or longer disease duration, but
results were not conclusive [27]. One study found that
smokers were at higher risk of pulmonary embolism, an outcome that is associated with higher mortality [28]. And
ﬁnally, one study found that smokers were at increased risk
of losing their sense of smell [29].
Multiple studies noted the high correlation between a
history of smoking and increased comorbidities, as well as
the association between multiple comorbidities and
increased risk of negative COVID-19 outcomes [25,
30–34]. One study that compared smokers, diabetics, and
diabetics who smoke found signiﬁcantly worse outcomes,
including increased risk of death, for the diabetics who
smoke compared to the other groups [27]. This ﬁnding highlights the crucial interaction between noncommunicable and
infectious diseases.

4. Discussion
The explosion of research on COVID-19 may best be seen in
NIH’s LitCovid database, which now has over 124,000 articles on the subject and sees over 2,000 new articles each
week. This unparalleled rate of research oﬀers a wealth of
information, but much of the information is incomplete as
we continue to learn about COVID-19 and its impacts. This
review sought to organize and update existing knowledge
and add to what has been done using more rigorous inclusion criteria.
The ﬁndings of this review indicate that smokers, including those who have quit, are at greater risk of developing
severe COVID-19 illness compared with never smokers. As
tobacco use and COVID-19 both dysregulate the RAS,
ever-smokers who contracted COVID-19 were more likely
to experience hospitalization, ICU admission, and death.
Furthermore, the interaction of COVID-19 and smoking
history was found to signiﬁcantly increase the risk posed to
individuals living with chronic diseases such as chronic liver
disease, diabetes, and cancer [21, 23, 27], a ﬁnding that has
not been documented in prior reviews.
In conducting this review, a number of future research
directions were identiﬁed. First, several other outcomes were
seen in studies that did not meet our inclusion criteria and
thus were not included in this review. However, these outcomes, including stroke, blood clots, heart attacks, sepsis,
mental illness, and neurological outcomes, deserve further
study. Second, evidence suggests other speciﬁc patient populations with a history of smoking, such as people living with
asthma and COPD, may also be at increased risk. Third,
research on COVID-19 among younger populations and
the impact of vaping on COVID-19 is still very limited. No
studies on vaping met our inclusion criteria. Considering
the growing evidence of long-lasting symptoms, neurological
side eﬀects, and other disabilities related to COVID-19,
more information on how COVID-19 impacts young adults
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is urgently needed. Additionally, while a few articles found
that noncombustible nicotine use such as hookah and vaping was correlated with increased incidence of COVID-19
[35, 36], little research has examined the association between
these forms of tobacco use and COVID-19 outcomes.
Finally, evidence suggests a dose-response relationship
between tobacco use and health outcomes. Therefore, dosage
should be considered more widely in analyses of the impact
of tobacco use on COVID-19 outcomes.
4.1. Strengths and Limitations. This systematic review
focused on the impact of tobacco use on COVID-19 outcomes, including hospitalization, ICU admission, mechanical ventilation, and mortality. It achieved this goal by using
appropriate search terms to gather available research, applying a rigorous methodical approach, and consolidating the
ﬁndings into useful results to inform public health policy.
However, there are limitations. With over 2,000 articles on
COVID-19 published each week, any review, including this
one, is inherently behind the latest research. In an eﬀort to
mitigate this limitation, preprints were included in the analysis. However, preprints have their own limitations, as they
are not yet peer-reviewed. Recognizing this limitation, we
presented results of preprints separately in Table 2. While
this review was able to include studies from a variety of
countries, it was still limited to English-language articles,
excluding work done in Chinese, Italian, Spanish, and other
languages. Additionally, the wide range of measurements
used across studies made comparison diﬃcult. For example,
while some studies separated current vs. former smokers,
others combined all participants with a history of tobacco
use into one pool. While this may solve the problem of small
samples, it may also dilute the results. Perhaps most importantly, the majority of studies relied on medical records,
which may be missing data or contain incomplete histories.
Lowe et al. [25] point out that patients with complete
records are more likely to be wealthy and regularly access
healthcare, potentially leading to an underestimate of the
impact of tobacco use on COVID-19 outcomes.

5. Conclusions
Tobacco use increases the risk of severe illness, hospitalization, and mortality due to COVID-19. Public health eﬀorts
to minimize these outcomes should include raising awareness of these risks, promoting the uptake of and increasing
access to tobacco cessation, encouraging tobacco users to
seek care early in their illness, and prioritizing vaccination
for those with a history of tobacco use. Some states within
the United States have prioritized tobacco users in vaccination eﬀorts. Given the ﬁndings of this review, we recommend expanding this policy.

Appendix
A. Search Terms
A.1. PubMed and LitCovid which Recognize Mesh Terms.
(“COVID-19”[Mesh] OR “Coronavirus Infections”[Mesh]
OR “SARS-CoV-2”[Mesh] OR “SARS-CoV-2” OR “SARS
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COV 2” OR “COVID-19” OR “COVID” OR “novel coronavirus”) AND (“Smoking Devices”[Mesh] OR “Smokers”[Mesh] OR “Tobacco Use”[Mesh] OR “Tobacco
Products”[Mesh] OR “Tobacco Smoke Pollution”[Mesh]
OR “Vaping”[Mesh] OR “Smoking” OR “tobacco” OR “vaping” OR “cigarette” OR “Juul” OR “smoke” OR “smoked”
OR “vape” OR “tobacco use”) AND (“Mortality”[Mesh]
OR “Hospitalization”[Mesh] OR “Outcomes” OR “Outcome” OR “mortality” OR “death” OR “hospitalization”
OR “hospitalized” OR “morbidity” OR “complication” OR
“complications”)
A.2. Scopus and Europe PMC (Limited to Preprints), which
Do Not Recognize Mesh Terms. (“coronavirus infections”
OR sars-cov-2 OR covid-19 OR covid OR “novel coronavirus”) AND (smoking OR tobacco OR vaping OR cigarette
OR juul OR smoke OR smoked OR vape OR “tobacco
use”) AND (mortality OR hospitalization OR outcomes
OR outcome OR death OR hospitalized OR morbidity OR
complication OR complications)
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